We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genzyme has completed a planned analysis of interim data from its pivotal clinical
trial of Myozyme, which is being studied for the treatment of Pompe disease.
Vical has announced that data from two Phase I trials support the advance of
the bivalent (two-plasmid) formulation of the company's vaccine against cytomegalovirus
(CMV) to Phase II trials in hematopoietic cell transplant (HCT) patients.
Neurochem's independent safety review board (ISRB) has issued a recommendation
to continue the company's North American Phase III clinical trial for Alzhemed
for the treatment of Alzheimer's disease (AD).
Amgen and Abgenix have announced the initiation of a Phase III clinical study
to evaluate the potential benefits of adding panitumumab, an experimental fully
human monoclonal antibody, administered every other week to bevacizumab (Avastin,
Genentech) and either oxaliplatin- (Eloxatin, sanofi-aventis) or irinotecan
(Camptosar, Pfizer)-based chemotherapy for the first-line treatment of metastatic
colorectal cancer.
The U.S. Patent and Trademark Office has issued Maxim Pharmaceuticals a patent
covering a method for identifying therapeutically active immunosuppressive agents
by screening for compounds that induce apoptosis in activated T or B cells.
Generex Biotechnology has announced that its wholly owned subsidiary, Antigen
Express, has received Australian Patent No. 778115 titled, "Hybrid Peptides
Modulate the Immune Response."
The FDA has granted orphan-drug status to BioAlliance Pharma's Transdrug (doxorubicin)
for the treatment of hepatocellular carcinoma, a potentially fatal form of liver
cancer.
GPC Biotech AG and Ingenium Pharmaceuticals AG have announced the joint receipt
of a grant totaling €2.2 million in committed funding from the German Ministry
for Education and Research through its BioChancePLUS program.
Vivus has announced results of a clinical pharmacology study conducted to evaluate
the hemodynamic responses (blood pressure and heart rate) to glyceryl trinitrate
(GTN) in subjects pretreated with placebo, avanafil (Vivus' investigational
PDE5 inhibitor) or sildenafil citrate (Viagra).